Positron emission tomography (PET): An update on applications in breast cancer

Breast Disease

Volumn 10, Issue 3-4, 1998, Pages 165-175

  Wahl, Richard L ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TRACER;

ANATOMICAL VARIATION; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST TUMOR; CAMERA; CANCER; DIAGNOSTIC IMAGING; HUMAN; LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR;

EID: 0031656010     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-1998-103-416     Document Type: Article

References (46)

1. Adler D, Wahl UL. New methods for imaging the breast: techniques, findings, and potential. AJR 1995; 164:19-30.
2. Macfarlane DJ, Cotton L, Ackermann RJ, et al. Triple-head 2-[18F]-2-deoxy-D-glucose SPECT: initia! evaluation in oncology and comparison to 18FDG PET. Radiology 1995; 194:425-429.
3. Wahl RL, Fisher SJ. In vivo comparison of breast cancer imaging radio-pharmaceuticals in breast cancer in the rodent model. J Nucl Med 1996; (abstract):36.
4. Beaney RP, Lammertsma AA, Jones T, et al. Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with, breast carcinoma. Lancet 1984; 1(8369):131-134.
5. Wilson CB, Lammertsma AA, McKenzie CG, et al. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 1992 (Mar 15); 52(6):1592-1597.
6. Wahl RL, Zasadny K, Koeppe RA, et al. Initial evaluation of Cu-62 PTSM as a tumor blood flow agent in man: comparison studies with 0-15 water. J Nucl Med 1993; 34(5):224.
7. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988; 169(1):45-48.
8. McGuire AH, Dehdashti F, Siegel BA, et al. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991; 32(8):1526-1531.
9. Minn H. Soini I. [18F]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Eur J Nucl Med 1989; 15(2): 61-66.
10. Wahl RL, Cody RL, Hutchins GD, et al. PET imaging of breast cancer with 18FDG. Radiology 1989; 173:419.
11. Kubota K, Matsuzawa T, Amemiya A, et al. Imaging of breast cancer with [18F]fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 1989; 13(6):1097-1098.
12. Wahl RL, Cody R, Hutchins GD, et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analog 2-[18F]-fiuoro-deoxy-2-D-glucose (FDG). Radiology 1991; 179:765-770.
13. Wahl RL, Henry CA, Ethier SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[18F]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology 1992; 183(3):643-647.
14. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancer-a PET study. J Nucl Med 1993; 34(1):1-6.
15. Brown RS, Wahl RL. Over-expression of GLUT-1 glucose transporter in human breast cancer: An immunohistochemical study. Cancer 1993; 72(10):2979-2985.
16. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993; 34:414-419.
17. Brown RS, Leung JY, Fisher S, et al. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between GLUT-1 expression and FDG uptake. J Nucl Med 1996; 37(6):1042-1047.
18. Brown RS, Leung JY, Fisher SJ, et al. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? J Nucl Med 1995; 36(10):1854-1861.
19. Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-[18]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 17(4):582-589.
20. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71(12):3920-3925.
21. Adler LP, Crowe JP, al-Kaisi NK, et al. Evaluation of breast masses and axillary lymph nodes with [18F] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187(3):743-750.
22. Adler LP, Faulhaber PF, Schnur KC, et al. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG PET. Radiology 1997; 203(2):323-327.
23. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 1995; 36:1766-1774.
24. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18Fluorodeoxyglucose in breast cancer. J Nucl Med 1996; 37:931-938.
25. Avril N, Dose J, Janicke DF, et al. Metabolic characterization of breast tumors with positron emission tomography using 18f fluorodeoxyglucose. J Clin Oncol 1996; 14:1848-1857.
26. Palmedo H, Bender H, Grunwald F, et al. Comparison of fluorine-18 fluorodexoyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumors. Eur J Nucl Med 1997; 24(9):1138-1145.
27. Wahl RL, Helvie MA, Chang AE, et al. Detection of breast cancer in women after augmentation mammoplasty using positron emission tomography: Initial clinical evaluation. J Nucl Med 1994; 35:872-875.
28. Leskinen-Kallio S, Nagren K, Lehikoinen P, et al. Uptake of 11C-methionine in breast cancer studied by PET. An association with the size of S-phase fraction. Br J Cancer 1991; 64(6):1121-1124.
29. Kole AC, Nieweg OE, Pruim J, et al. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[11C]tyrosine PET. J Nucl Med 1997; 38(5):692-696.
30. Wahl RL, Kaminski MS, Ethier SP, et al. The potential of 2-deoxy-2[18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med 1990; 31(11):1831-1835.
31. Wahl RL, Cody RL, August D. Initial evaluation of FDG PET for the staging of the axilla in newly-diagnosed breast carcinoma patients. J Nucl Med 1991; 32(5):981.
32. Tse NY, Hoh CK, Hawkins RA, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216(1):27-34.
33. Utech CI, Young CS, Winter P. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996; 22(12):1588-1593.
34. Crippa F, Agresti R, Seregni E, et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998; 39(1):4-8.
35. Avril N, Dose J, Janicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996; 88(17):1204-1209.
36. Griffeth LK, Rich KM, Dehdashti F, et al. Brain metastases from non-central nervous system tumors: evaluation with PET, Radiology 1993; 186(1):37-44.
37. Wald J, Wahl RL. Detection of brachial plexus metastases with PET. Neurology 1994; 44:A307.
38. Bender H, Kirst J, Palmedo H, et al. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997; 17(3B):1687-1692.
39. Wahl RL, Zasadny KR, Hutchins GD, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography (PET): initial evaluation. J Clin Oncol 1993; 11(11):2101-2111.
40. Jansson T, Westlin JE, Ahlstrom H, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995; 13(6): 1470-1477.
41. Freifelder R, Karp JS. Dedicated PET scanners for breast imaging. Physics in Medicine and Biology 1997; 42(12):2463-2480.
42. Raylman RR, Ficaro EP, Wahl RL. Stereotactic coordinates from ECT sinograms for radionuclide-guided breast biopsy. J Nucl Med 1996; 37(9):1562-1567.
43. Khalkhali I, Mishkin FS, Diggles LE, et al. Radionuclide-guided stereotactic prebiopsy localization of nonpalpable breast lesions with normal mammograms. J Nucl Med 1997; 38(7):1019-1022.
44. Wahl RL, Quint LE, Cieslak RD, et al. "Anatometabolic" tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med 1993; 34(7):1190-1197.
45. Raylman RR, Fisher S, Brown RS, et al. Fluorine-18-fluorodeoxyglucose-guided breast cancer surgery with a positron-sensitive probe: Validation in preclinical studies. J Nucl Med 1995; 36(10):1869-1874.
46. Raylman RR, Wahl RL. Evaluation of ion-implemented-silicon detectors for use in intraoperative positron-sensitive probes. Med Phys 1996; 23(11):1889-1895.